Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc.
Explore linked clinical trials.8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Breast Cancer PSMA PET | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Early phase 1 | 2026-08-06 | NCT06586047 | |
| Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate adenocarcinoma, prostate cancer, prostate disorder | Active, not recruiting | Not stated | 2026-08-05 | NCT04030338 | |
| Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2026-03-30 | NCT03471650 | |
| PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 / Phase 3 | 2026-03-02 | NCT03495427 | |
| Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 4 | 2026-01-29 | NCT06099093 | |
| Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy | prostate adenocarcinoma | Recruiting | Phase 4 | 2025-10-24 | NCT05919329 | |
| PET/MRI for the Staging of Newly Diagnosed Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Early phase 1 | 2025-05-23 | NCT03392181 | |
| PSMA-PET Guided Radiotherapy | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 / Phase 3 | 2025-03-13 | NCT03525288 |